Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 20/20 | 0.69 |
| ▸ | ITGAV | P06756 | 20/20 | 0.69 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.64 |
| ▸ | ITGB5 | P18084 | 7/20 | 0.57 |
| ▸ | ITGB6 | P18564 | 7/20 | 0.57 |
| ▸ | ITGB8 | P26012 | 5/20 | 0.57 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6262063 | 0.92 | ITGB3 (0.74) | ITGB3ITGAVITGA2BITGB5ITGB6 | |
| Hydrochloric Acid SCHEMBL6424214 | 0.91 | ITGB3 (0.72) | ITGB3ITGAVITGA2BITGB5ITGB6 | |
| Hydrochloric Acid SCHEMBL29416400 | 0.91 | ITGB3 (0.72) | ITGB3ITGAVITGA2BITGB5ITGB6 | |
| SCHEMBL15397316 | 0.91 | ITGB3 (0.79) | ITGB3ITGAVITGA2BITGB5ITGB6 | |
| Hydrochloric Acid SCHEMBL6425719 | 0.89 | ITGB3 (0.77) | ITGB3ITGAVITGA2BITGB5ITGB6 | |
| SCHEMBL21329747 | 0.89 | ITGB3 (0.77) | ITGB3ITGAVITGA2BITGB5ITGB6 | |
| Hydrochloric Acid SCHEMBL6422102 | 0.89 | ITGB3 (0.77) | ITGB3ITGAVITGA2BITGB5ITGB6 | |
| Hydrochloric Acid SCHEMBL20487381 | 0.89 | ITGB3 (0.77) | ITGB3ITGAVITGA2BITGB5ITGB6 | |
| SCHEMBL6422552 | 0.89 | ITGB3 (0.77) | ITGB3ITGAVITGA2BITGB5ITGB6 | |
| Hydrochloric Acid SCHEMBL6792186 | 0.88 | ITGB3 (0.76) | ITGB3ITGAVITGA2BITGB5ITGB6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025130549-A1 | LIGAND TARGETING INTEGRIN αVβ6, CONJUGATE AND COMPOSITION, AND USES THEREOF | 北京炫景瑞医药科技有限公司 | 2025-06-26 | — | — | WO | disclosed |
| CN-120192313-A | Ligand, conjugate, composition and use of targeting integrin alpha v beta 6 | 北京炫景瑞医药科技有限公司 | 2025-06-24 | — | — | CN | disclosed |
| WO-2025072539-A1 | AMINO ACID COMPOUNDS WITH NITROGEN LINKERS AND USES THEREOF | PLIANT THERAPEUTICS, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| CN-117642396-A | Alpha V beta 6 and alpha V beta 1 integrin inhibitors and uses thereof | 戴斯分子SV有限公司 | 2024-03-01 | — | — | CN | disclosed |
| US-11702652-B2 | Enzymatic encoding methods for efficient synthesis of large libraries | NUEVOLUTION A/S (DK) | 2023-07-18 | — | — | US | disclosed |
| US-11702652-B2 | Enzymatic encoding methods for efficient synthesis of large libraries | NUEVOLUTION A/S (DK) | 2023-07-18 | — | — | US | disclosed |
| US-11530180-B2 | Alpha-5 beta-1 inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-12-20 | — | — | US | disclosed |
| CN-110167934-B | Cyclobutane-and azetidine-containing monocyclic and spiro compounds as alpha V integrin inhibitors | 百时美施贵宝公司 | 2022-06-10 | — | — | CN | disclosed |
| US-20220144853-A1 | IMIDAZOLINE DERIVATIVES AS CXCR4 MODULATORS | Université de Paris (FR) | 2022-05-12 | — | — | US | disclosed |
| EP-3947394-A1 | IMIDAZOLINE DERIVATIVES AS CXCR4 MODULATORS | Université de Paris (FR) | 2022-02-09 | — | — | EP | disclosed |
| EP-1979342-A1 | COMPOUNDS FOR THE INHIBITION OF INTEGRINS AND USE THEREOF | Jerini AG (DE) | 2008-10-15 | — | — | EP | disclosed |
| US-7351711-B2 | Tricyclic indanyls as integrin inhibitors | JANSSEN PHARMACEUTICAL, N.V. (BE) | 2008-04-01 | — | — | US | disclosed |
| US-7351711-B2 | Tricyclic indanyls as integrin inhibitors | JANSSEN PHARMACEUTICAL, N.V. (BE) | 2008-04-01 | — | — | US | disclosed |
| US-20080058359-A1 | Piperidinyl compounds that selectively bind integrins | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-03-06 | — | — | US | disclosed |
| US-20080058359-A1 | Piperidinyl compounds that selectively bind integrins | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-03-06 | — | — | US | disclosed |
| US-20070282101-A1 | Indazole compounds | ABBVIE INC. | 2007-12-06 | — | — | US | disclosed |
| WO-2007088041-A1 | COMPOUNDS FOR THE INHIBITION OF INTEGRINS AND USE THEREOF | JERINI AG (DE) | 2007-08-09 | — | — | WO | disclosed |
| WO-2007062664-A2 | ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES | NUEVOLUTION A/S (DK) | 2007-06-07 | — | — | WO | disclosed |
| EP-1506779-A1 | (3-(4-(Pyridin-2-ylamino)-butyryl)-2,3,4,4a,9,9a-hexahydro-1H-3-aza-fluoren-9-yl)-acetic acid derivatives and related tricyclic indanyls as alphaVbeta3 and alphaVbeta5 integrin inhibitors for the treatment of cancer and unstable angina | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-16 | — | — | EP | disclosed |
| WO-2004020435-A1 | PIPERIDINYL COMPOUNDS THAT SELECTIVELY BIND INTEGRINS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058359-A1 | Piperidinyl compounds that selectively bind integrins | ITGB3, ITGAV, ITGA2B | ITGB3 1/4885ITGAV 2/4885ITGA2B 3/4885 |
| US-20220144853-A1 | IMIDAZOLINE DERIVATIVES AS CXCR4 MODULATORS | CXCR4, CXCL12, CXCR1 | ITGB3 887/4885ITGAV 934/4885ITGA2B 484/4885 |
| US-20070282101-A1 | Indazole compounds | CYP3A43, CYP3A7, UGT1A1 | ITGB3 1031/4885ITGAV 3024/4885ITGA2B 1849/4885 |
| US-11530180-B2 | Alpha-5 beta-1 inhibitors | SCN5A, PSMA5, API5 | ITGB3 957/4885ITGAV 1756/4885ITGA2B 1033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.